VKTX Share Price | Viking Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Viking Therapeutics, Inc.?

Market Cap: As of Jun 18, Viking Therapeutics, Inc. has a market capitalization of 2,968.34 million, categorizing it as a Small Cap company.Recent Quarterly Performance: For the latest four quarters, Viking Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -128.24 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 880.28 million and total assets of 908.32 million.

Q: What does Viking Therapeutics, Inc. do?

Overview:Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap company.Financial Snapshot:Most recent Net Profit: -46 Million (Quarterly Results - Mar 2025) Market cap: USD 2,968.34 Million (Small Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.01 Return on Equity: -15.14% Price to Book: 3.50Contact Details:Address: 12340 El Camino Real Ste 250, SAN DIEGO CA: 92130-3093 Tel: ['1 858 7044660', '1 858 7044672'] Fax: 1 302 6365454 Website: http://www.vikingtherapeutics.com

Q: Is Viking Therapeutics, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, driven by a bullish MACD on the weekly timeframe and bullish moving averages on the daily timeframe. However, the monthly MACD and Bollinger Bands indicate bearish conditions, suggesting mixed signals across different periods. The stock has underperformed the S&P 500 over the year and year-to-date, with returns of -52.48% and -13.94% respectively, but has significantly outperformed over the 3-year and 5-year periods with returns of 687.05% and 498.10%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.28 M

Shareholding (Dec 2025)

FII

13.18%

Held by 195 FIIs

DII

48.71%

Held by 48 DIIs

Promoter

1.00%

How big is Viking Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Viking Therapeutics, Inc. has a market capitalization of $2.97 billion, with net sales of $0 and a net profit of -$128.24 million over the last four quarters. The company reported shareholder's funds of $880.28 million and total assets of $908.32 million as of Dec 24.

View full answer

What does Viking Therapeutics, Inc. do?

22-Jun-2025

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. It has a market cap of approximately $2.97 billion and reported a net profit loss of $46 million as of March 2025.

View full answer

Who are in the management team of Viking Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Viking Therapeutics, Inc. includes Dr. Lawson Macartney (Independent Chairman), Dr. Brian Lian (President and CEO), and Directors Matthew Foehr, S. Kathy Rouan, Charles Rowland, and J. Matthew Singleton. They oversee the company's strategic direction and operations.

View full answer

Is Viking Therapeutics, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, the trend has shifted to mildly bullish due to positive indicators on shorter timeframes, despite mixed signals from longer-term metrics and significant underperformance against the S&P 500 over the past year.

View full answer

Compare Viking Therapeutics, Inc. with Similar Stocks

89bio, Inc.Mirum Pharmaceuticals, Inc.SAGE Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 4,161 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.10

Return on Equity

-56.28%

Price to Book

6.51

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-158 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-4.12%

6 Months

25.0%

1 Year

10.49%

2 Years

-48.62%

3 Years

175.15%

4 Years

865.88%

5 Years

424.15%

Viking Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-248.49%

EBIT to Interest (avg)

-92.99

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

85.41%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.51

EV to EBIT

-8.79

EV to EBITDA

-8.79

EV to Capital Employed

-51.93

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-56.28%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bearish

Bollinger Bands

Bearish

Moving Averages

Bullish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 101 Schemes (37.09%)

Foreign Institutions

Held by 195 Foreign Institutions (13.18%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -345.48% vs -43.90% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-164.60",
          "val2": "-46.10",
          "chgp": "-257.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-157.70",
          "val2": "-35.40",
          "chgp": "-345.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -226.91% vs -28.06% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-392.90",
          "val2": "-150.60",
          "chgp": "-160.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-359.60",
          "val2": "-110.00",
          "chgp": "-226.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-164.60

-46.10

-257.05%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-157.70

-35.40

-345.48%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -345.48% vs -43.90% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-392.90

-150.60

-160.89%

Interest

0.10

Exceptional Items

0.00

Consolidate Net Profit

-359.60

-110.00

-226.91%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -226.91% vs -28.06% in Dec 2024

All Annual Results

Company CV

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

Company Coordinates

Company Details

12340 El Camino Real Ste 250 , SAN DIEGO CA : 92130-3093

Tel: 1 858 70446601 858 7044672

http://www.vikingtherapeutics.com

Registrar Details